Ever Fortune.AI Co., Ltd.
TTPEX:684153.90
TWD
-0.30
(-0.55%)
ISIN
TW0006841000
Return %
Stock
S&P 500
1Y
-20.27
14.20
3Y
-40.24
81.12
5Y
-59.47
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Yue Cheng Li
- Full Time Employees
- 50
- Sector
- Technology services
- Industry
- Packaged software
- Address
- No.360, Jingmao Rd Taichung TX Taiwan 406040
- IPO Date
- Mar 1, 2023
- Website
- everfortuneai.com.tw
- Similar Companies
- Business
- Ever Fortune.AI Co., Ltd. (6841.TWO) develops and provides medical artificial intelligence software solutions and cloud-based biomedical platforms principally in Taiwan and China; the company offers medical big data analysis, customized AI technology services, PACS picture archiving and communication systems, and cloud medical platforms that support image viewing, workflow acceleration, remote access, collaboration, reporting, and analytics for healthcare providers, insurers, and genetic testing partners. Core products include the RTsuite CT HCAP-Segmentation System and RTsuite CT HN-Segmentation System for radiotherapy planning; NeuroSuite CT ICH Assessment System for intracranial hemorrhage detection; Cardiosuite SPECT Myocardial Perfusion Agile Workflows, ECG Analysis Software, Cardiosuite CTA Acute Aortic Syndrome Assessment System, STEMI Detection Software, and Intelligent Cardiothoracic Ratio (iCTR) Assessment System for cardiac diagnostics; ChestSuite XR Assessment System for chest X-rays; Computer-Aided Bone Age Diagnosis System; radiographic bone age-assisted interpretation and height prediction system; ultrasound breast tumor auxiliary classification system; computer tomography liver cancer metastasis risk management system; liver fibrosis evaluation system; and irregular cardiac fibrillation interpretation tools. Founded in 2018 and headquartered at 8F, No. 360, Sec. 1, Jingmao Rd., Beitun Dist., Taichung City, Taiwan, the company primarily serves hospitals, radiology departments, cardiovascular centers, and insurance firms through AI-driven diagnostic assistance that enhances clinical efficiency and decision-making accuracy using deep learning on medical imaging and big data. In March 2025, Ever Fortune.AI announced plans to establish a joint venture company with Phison Electronics Corp. to expand AI applications potentially beyond healthcare; the firm listed on the Taipei Exchange in September 2021 and continues to secure regulatory approvals, including U.S. FDA clearances for products like EFAI HCAPSeg and iCTR software in 2023, while growing revenues from medical AI and biotechnology segments, with 2024 sales reaching approximately TWD 323 million in Taiwan and TWD 14 million in the United States.